Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.67 |
| ▸ | HTR1D | P28221 | 4/20 | 0.60 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.60 |
| ▸ | HTR2C | P28335 | 5/20 | 0.57 |
| ▸ | HTR2B | P41595 | 4/20 | 0.57 |
| ▸ | HTR1A | P08908 | 7/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | HTR6 | P50406 | 2/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR1E | P28566 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1163214 | 0.84 | HTR2A (0.46) | HTR2AHTR1DTRPM8HTR2CHTR1A | |
| SCHEMBL4395931 | 0.82 | HTR2A (0.57) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL25434919 | 0.82 | HTR1A (0.67) | HTR2AHTR1DHTR2CHTR2BHTR1A | |
| SCHEMBL30483758 | 0.82 | HTR1A (0.67) | HTR2AHTR1DHTR2CHTR2BHTR1A | |
| SCHEMBL25281662 | 0.81 | HTR2A (0.74) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL29511892 | 0.81 | HTR2A (1.00) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL12558834 | 0.81 | HTR2A (1.00) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL1163398 | 0.80 | HTR2A (0.66) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL8544006 | 0.80 | HTR2A (0.73) | HTR2AHTR1DTRPM8HTR2CHTR2B | |
| SCHEMBL16303671 | 0.79 | HTR2A (0.42) | HTR2AHTR1DTRPM8HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| EP-2464227-A1 | COMPOUNDS AND METHODS OF USE THEREOF | Galenea Corporation (US) | 2012-06-20 | — | — | EP | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| WO-2011019738-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2011-02-17 | — | — | WO | disclosed |
| EP-2254865-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | ORGANIX, INC. (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
| WO-2009102805-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | ORGANIX INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR1D 154/4885TRPM8 2766/4885 |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HTR2A 27/4885HTR1D 50/4885TRPM8 2894/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR1D 154/4885TRPM8 2766/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | HTR2A 34/4885HTR1D 154/4885TRPM8 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.